PMC:7784786 / 6453-7094
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
234 | 21-31 | Chemical | denotes | itolizumab | MESH:C000597346 |
235 | 167-177 | Chemical | denotes | itolizumab | MESH:C000597346 |
236 | 390-400 | Chemical | denotes | itolizumab | MESH:C000597346 |
237 | 517-527 | Chemical | denotes | itolizumab | MESH:C000597346 |
238 | 139-155 | Disease | denotes | pleural effusion | MESH:D010996 |
239 | 342-358 | Disease | denotes | pleural effusion | MESH:D010996 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T17 | 139-155 | Phenotype | denotes | pleural effusion | http://purl.obolibrary.org/obo/HP_0002202 |
T18 | 342-358 | Phenotype | denotes | pleural effusion | http://purl.obolibrary.org/obo/HP_0002202 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T59 | 0-127 | Sentence | denotes | Patient 1 (A) Before itolizumab (D0): diffuse Interstitial-alveolar infiltrate in both lung fields, predominantly in the bases. |
T60 | 128-331 | Sentence | denotes | Minor left pleural effusion. (B) After itolizumab (48 h): radiological improvement with decreased diffuse infiltrate and radio-opacity at the top of both lungs and in both lung bases, in less proportion. |
T61 | 332-368 | Sentence | denotes | The minor pleural effusion persists. |
T62 | 369-641 | Sentence | denotes | Patient 3 (C) Before itolizumab (D0): alveolar interstitial inflammatory infiltrate in both lung fields, predominantly on the right side. (D) After itolizumab (48 h): radiological improvement with significant decrease of the alveolar interstitial infiltrate of both lungs. |